Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kent D Stewart

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Journal of Medicinal Chemistry|May 1, 2009
Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitorsJohn T Randolph, Charles A Flentge, Peggy P Huang, et al.
Bioorganic & Medicinal Chemistry Letters|April 3, 2012
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase familiesMichael L Curtin, Robin R Frey, H Robin Heyman, et al.
Journal of Medicinal Chemistry|June 10, 2005
Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitorsClarence J Maring, Vincent S Stoll, Chen Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2013
Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motifA Chris Krueger, John T Randolph, David A DeGoey, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinasesSteve D Fidanze, Scott A Erickson, Gary T Wang, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Thienopyridine urea inhibitors of KDR kinaseH Robin Heyman, Robin R Frey, Peter F Bousquet, et al.
Journal of Medicinal Chemistry|February 4, 2005
Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moietiesArthur Gomtsyan, Erol K Bayburt, Robert G Schmidt, et al.
Journal of Medicinal Chemistry|January 18, 2018
Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral BioavailabilityJohn T Randolph, A Chris Krueger, Pamela L Donner, et al.
Journal of Medicinal Chemistry|October 27, 2006
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesZhonghua Pei, Xiaofeng Li, Thomas W von Geldern, et al.
Journal of Medicinal Chemistry|September 16, 2005
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitorsYujia Dai, Yan Guo, Robin R Frey, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Journal of Medicinal Chemistry|May 1, 2009
Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitorsJohn T Randolph, Charles A Flentge, Peggy P Huang, et al.
Bioorganic & Medicinal Chemistry Letters|April 3, 2012
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase familiesMichael L Curtin, Robin R Frey, H Robin Heyman, et al.
Journal of Medicinal Chemistry|June 10, 2005
Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitorsClarence J Maring, Vincent S Stoll, Chen Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2013
Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motifA Chris Krueger, John T Randolph, David A DeGoey, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinasesSteve D Fidanze, Scott A Erickson, Gary T Wang, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Thienopyridine urea inhibitors of KDR kinaseH Robin Heyman, Robin R Frey, Peter F Bousquet, et al.
Journal of Medicinal Chemistry|February 4, 2005
Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moietiesArthur Gomtsyan, Erol K Bayburt, Robert G Schmidt, et al.
Journal of Medicinal Chemistry|January 18, 2018
Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral BioavailabilityJohn T Randolph, A Chris Krueger, Pamela L Donner, et al.
Journal of Medicinal Chemistry|October 27, 2006
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesZhonghua Pei, Xiaofeng Li, Thomas W von Geldern, et al.
Journal of Medicinal Chemistry|September 16, 2005
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitorsYujia Dai, Yan Guo, Robin R Frey, et al.
Pageof 7